About this journal
Aims and scope
*Please note that Expert Review of Precision Medicine and Drug Development converted to a full Open Access journal from Volume 8 (2023). Previous volumes will continue to provide access through a Pay to Read model.
Expert Review of Precision Medicine and Drug Development [e-ISSN 2380-8993] is an international open access journal publishing rigorously peer-reviewed review articles and original papers on the development and clinical application of medicine to be used in a personalised therapy setting.
In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, Expert Review of Precision Medicine and Drug Development supports the necessity to identify patients responsive to treatments and treat patient populations using a tailored approach.
Articles focus on the following key areas:
- Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this;
- Clinical trials within personalised therapy and drug development;
- Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment;
- Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies;
- Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
Please note that the journal does not publish case reports, case series or animal studies
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Review of Precision Medicine and Drug Development, part of the Expert Collection brand.
For any pre-submission enquiries, please contact the Commissioning Editor.
Journal metrics
Usage
- 29K annual downloads/views
Citation metrics
- 1.0 (2023) Impact Factor
- 1.3 (2023) 5 year IF
- 2.3 (2023) CiteScore (Scopus)
- 0.144 (2023) SNIP
- 0.257 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief:
Professor Liang Cheng (MD),Vice Chair for Translational Research, Brown University, Providence, RI, USA.
Research Interests: Pathology; Urology; Genitourinary Cancers; Molecular Diagnostics
Editorial Board Members:
Professor Juan-Manuel Anaya (MD, PhD), Universidad del Rosario, Bogotá, Colombia.
Research Interests: Genetics; Autoimmune Diseases; Translational Medicine; Immunogenetics
Professor Simone Appenzeller (MD, PhD), University of Campinas, Campinas, Brazil.
Research interests: lupus erythematosus, autoimmune disease, autoinflammatory disease, CNS involvement
Dr William CS Cho (PhD), Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong.
Research Interests: Molecular Oncology; MicroRNA; Lymphoma; Tumor Marker Discovery; Bioinformatics
Dr Alessia Cimadamore (MD, PhD), Polytechnic University of the Marche Region, Ancona, Italy.
Research Interests: Molecular Biomarkers; Prostate Cancer; Renal Cell Carcinoma; Bladder Cancer
Dr Dimitar Dimitrov (PhD), University of Pittsburgh, Pittsburgh, PA, USA.
Research Interests: Novel Human Monoclonal Antibodies; Therapeutics Antibodies in Clinical Trials
Professor Henk-Jan Guchelaar (PharmD, PhD), Leiden University Medical Center, Leiden, The Netherlands.
Research Interests: Pharmacogenetics; Pharmacogenetic Biomarkers; Personalised Therapeutics
Professor Michael A Jacobs (PhD), Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Research Interests: Brain Cancer; Brain Metastases; Breast Imaging; Locally Advanced Breast Cancer; Radiomics
Professor Adrian Llerena (PhD), Extremadura University Hospital and Medical School, Badajoz, Spain.
Research Interests: Pharmacogenetics; Pharmacogenomics; Genotyping; Psychopharmacology
Dr Antonio Lopez-Beltran (MD), Cordoba University Medical School, Cordoba, Spain.
Research Interests: Urologic Cancer, Uropathology, Bladder Cancer, Prostate Cancer
Professor Anil K Malhotra (MD), The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Research Interests: Neuroscience; Psychiatry; Schizophrenia; Anti-psychotic Drugs; Molecular Genetics
Dr Nafees Malik (MD), Juvenescence, Ormskirk, UK.
Research Interests: Gene therapy; T-cell Therapies in Oncology; Biotech
Professor Arduino A Mangoni (MD, PhD), Flinders University and Flinders Medical Centre, South Australia, Australia.
Research Interests: Clinical Pharmacology; Cardiology; Drug Safety; Drug Discovery; Biomarkers
Dr Francesco Massari (MD), Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Research Interests: Genitourinary Cancer
Professor Mark McCarthy (MD), University of Oxford, Oxford, UK.
Research Interests: Diabetes; Gene Identification in Type 2 Diabetes; Personalised Medicine; Sequencing; Genetic Epidemiology
Professor Rodolfo Montironi (MD), Polytechnic University of the Marche Region, Ancona, Italy.
Research Interests: Genitourinary Tumor Pathology; Urology; Prostate Cancer; Urologic Oncology
Professor Edouard Nice (PhD), Monash University, Victoria, Australia.
Research Interests: Biomarker Discovery and Validation; Colorectal Cancer; Biosensor Analysis; Proteomics
Professor Shuji Ogino (MD, PhD), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Research Interests: Molecular Diagnostics; Precision Public Health; Colorectal Cancer; Transdisciplinary Epidemiology
Professor Godefridus J Peters (PhD), VU University Medical Center, Amsterdam, The Netherlands.
Research Interests: Cancer; Anti-Cancer Drugs; Cancer Biomarkers; Biotechnology
Professor Sir Munir Pirmohamed (PhD), University of Liverpool, Liverpool, UK.
Research Interests: Pharmacogenetics; Pharmacogenomics; Drug Safety; Precision Medicine; HLA
Professor Etheresia Pretorius (PhD), Stellenbosch University, Stellenbosch, South Africa.
Research Interests: Inflammatory Markers; Nanobiosensors; Platelets; Scanning Electron Microscopy
Professor Shahrokh Shariat (MD), Medical University of Vienna, Vienna, Austria.
Research Interests: Urologic Oncology; Markers; Early Detection; Translational Research; Outcomes Research
Professor Catherine Sherwin (PhD), Wright State University, Dayton Children's Hospital, Dayton, OH,USA.
Research Interests: Paediatrics; Toxicology; Antibiotics, Immunosuppressants, Antiepileptics; Pharmacometrics
Dr Jean-Claude Tardif (MD), Montreal Heart Institute, Montreal, Canada.
Research Interests: Cardiovascular Disease; Atherosclerosis; Personalised Medicine; Biomarkers
Professor Brian Tomlinson (MD), The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong.
Research Interests: Lipid Disorders; Hypertension; Personalised Medicine
Dr Tian Zhang (MD), Duke Cancer Institute, Durham, NC, USA.
Research Interests: Medical Oncology; Genitourinary Cancers
Abstracting and indexing
Expert Review of Precision Medicine and Drug Development is included in the following abstracting and indexing services:
Scopus; Emerging Sources Citation Index (ESCI).
Open access
Expert Review of Precision Medicine and Drug Development is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
News and offers
- Discuss your submission with Commissioning Editor Felicity Poole
Continuous publication
Associated with:
- Expert Review of Molecular Diagnostics (2001 - current)
- Expert Review of Proteomics (2004 - current)
- Expert Review of Anticancer Therapy (2001 - current)
- Expert Review of Clinical Pharmacology (2008 - current)
Advertising information
Would you like to advertise in Expert Review of Precision Medicine and Drug Development?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Expert Review of Precision Medicine and Drug Development.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors